Skip to content

Spinal Stimulation for Chronic Complete Tetraplegia

Non-invasive Spinal Cord Stimulation Combined With Activity-based Therapy in Chronic Complete High Level Spinal Cord Injury

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05522920
Acronym
Complete TESCS
Enrollment
12
Registered
2022-08-31
Start date
2022-08-31
Completion date
2024-12-31
Last updated
2022-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Cord Injuries

Brief summary

The purpose of this study is investigate the acceptability and effectiveness of transcutaneous spinal cord stimulation in people with complete high level spinal cord injury.

Interventions

OTHERTherapy with and without spinal cord stimulation

Conventional therapy only will be followed with conventional therapy combined with electrical spinal cord stimulation.

Sponsors

International Spinal Research Trust
CollaboratorOTHER
NHS Greater Glasgow and Clyde
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

All participants will receive study intervention

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Willing and able to give informed consent for participation in the study * Aged ≥18 years * Injury level C3-C7, American Spinal Cord injury Association Impairment Scale (ASIA) A * ≥1 year post-injury * Medically stable, cognitively intact, and able to breathe independently * Able to attend all sessions two or three times per week, for 2 h sessions and assessments

Exclusion criteria

* Any implanted active metallic device including, but not limited to neurostimulators, cochlear implants, pacemakers, implantable defibrillators, or drug delivery pumps * Possible, suspected, or confirmed pregnancy and/or lactation * Recent history or fracture, contractures or pressure sore, deep vein thrombosis (DVT) or urinary tract, or other infection that may interfere with the intervention and training * History of epilepsy and/or seizures * Severe spasticity which has been unstable over the 3 months prior to enrolment and is not expected to change and/or taking varying doses of anti-spasticity medications which could not be tapered to a stable dose and are not expected to change * Botulinum toxin injections within 6 months of participation * Non-injury related neurological impairment * Clinically significant severe depression in spite of treatment * Cardiovascular disease * Autonomic dysreflexia that is severe, ongoing, and has required medical treatment within the past month * Skin conditions or allergies that may affect electrode placement * Do not understand English * Received a stem cell treatment or other treatment that could possibly promote or attenuate neuroplastic changes in spinal or cortical function, within ≥2 years of enrolment; beyond this period, they may be included, provided the treatment was conducted in an accredited facility with proper ethics and regulatory approval. * Involved in any other study involving stimulation of the spinal cord within 6 months of enrolment * Information regarding recent rehabilitation or exercise programmes that participants may currently be engaged in will be discussed with clinical staff and fully documented for each participant

Design outcomes

Primary

MeasureTime frameDescription
Acceptance26 weeks at the end of interventionWhether the treatment protocol is acceptable by people with complete tetraplegia. This will be assessed using semi structured interview results of which will be analysed qualitatively to determine the number of participants who would use the therapy on an ongoing basis.

Secondary

MeasureTime frameDescription
Clinical effectiveness of spinal cord stimulation using GRASSP tool26 and 38 weeks, at the end of intervention and at follow up respectivelyEffectiveness of spinal cord stimulation in inducing changes in functional outcome. This will be assessed using the Graded and Redefined Assessment of Strength, Sensibility, and Prehension (GRASSP tool). The unit is based on the GRASSP measurement scale.
Neurophysiological change26 and 38 weeks, at the end of intervention and at follow up respectivelyEffectiveness of spinal cord stimulation in inducing changes in Neurophysiological equivalence of volitional movement. This will be assessed using changes in amplitude in mV of transcranial magnetic stimulation.
Spasticity26 weeks at the end of interventionChanges in upper limb muscle tone using change in the Modified Ashworth Scale.
Autonomic function26 weeks at the end of interventionChanges in autonomic function will be assessed using changes in the AUTONOMIC STANDARDS ASSESSMENT FORM of the International Spinal Cord Injury Data Set.
Change in perceived health status26 weeks at the end of interventionThe effect of the study on perceived health status of the participants will be assessed using QUALITY OF LIFE BASIC DATA SET of the International Spinal Cord Injury Data Set.
Sensation26 weeks at the end of interventionChange in sensation due to the intervention. This will be assessed using change the sensory score of the International Standards for Neurological classification of SCI (ISNCSCI)

Contacts

Primary ContactMariel Purcell, Consultant
margaret.purcell@ggc.scot.nhs.uk+44 141 201 2536
Backup ContactBethel C Osuagwu, PhD
bethel.osuagwu@gmail.com+44 7944142407

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026